US-based BNY Mellon Investment Management is launching an actively managed thematic fund which will invest in companies that are developing gene therapy, gene editing and gene modulation treatments.
The USD 2.2trn asset manager notes a demand for thematic funds in the Nordics, especially in the context of responsibility, director of Nordic distribution Viktoria von Kunow says.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for AMWatch has now started
With your free trial you get:
Full access to all locked articles on AMWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.